Androgen receptor expression in prostate cancer stem cells: Is there a conundrum?

Nima Sharifi, Elaine M. Hurt, William L. Farrar

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Androgen deprivation therapy (ADT) is standard frontline therapy for metastatic prostate cancer. However, prostate cancer progresses to a castrate-resistant state. The response of prostate cancer to androgen deprivation is mediated by the androgen receptor (AR). Castrate-resistant disease is marked by a gain-of-function in AR and AR reactivation. The stem cell hypothesis of cancer would therefore predict that AR should be expressed in the prostate cancer stem cell, since genetic selection for gain-of-function changes in AR, such as AR gene amplification, should occur at the level of the stem cell population. Initial reports characterizing prostate cancer stem cells suggest that AR is not expressed in this population, which is an apparent conundrum. Here, we examined the CD44+/24- LNCaP putative stem cell population by in-cell Western and show that AR is expressed at the protein level. Our findings suggest that at least a subset of prostate cancers express AR in the putative stem cell population.

Original languageEnglish (US)
Pages (from-to)921-923
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume62
Issue number5
DOIs
StatePublished - Oct 2008

Fingerprint

Neoplastic Stem Cells
Androgen Receptors
Stem cells
Prostatic Neoplasms
Stem Cells
Population
Androgens
Gene Amplification
Genetic Selection

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Androgen receptor expression in prostate cancer stem cells : Is there a conundrum? / Sharifi, Nima; Hurt, Elaine M.; Farrar, William L.

In: Cancer Chemotherapy and Pharmacology, Vol. 62, No. 5, 10.2008, p. 921-923.

Research output: Contribution to journalArticle

Sharifi, Nima ; Hurt, Elaine M. ; Farrar, William L. / Androgen receptor expression in prostate cancer stem cells : Is there a conundrum?. In: Cancer Chemotherapy and Pharmacology. 2008 ; Vol. 62, No. 5. pp. 921-923.
@article{0264603ba12f420ba8937a452c269f5f,
title = "Androgen receptor expression in prostate cancer stem cells: Is there a conundrum?",
abstract = "Androgen deprivation therapy (ADT) is standard frontline therapy for metastatic prostate cancer. However, prostate cancer progresses to a castrate-resistant state. The response of prostate cancer to androgen deprivation is mediated by the androgen receptor (AR). Castrate-resistant disease is marked by a gain-of-function in AR and AR reactivation. The stem cell hypothesis of cancer would therefore predict that AR should be expressed in the prostate cancer stem cell, since genetic selection for gain-of-function changes in AR, such as AR gene amplification, should occur at the level of the stem cell population. Initial reports characterizing prostate cancer stem cells suggest that AR is not expressed in this population, which is an apparent conundrum. Here, we examined the CD44+/24- LNCaP putative stem cell population by in-cell Western and show that AR is expressed at the protein level. Our findings suggest that at least a subset of prostate cancers express AR in the putative stem cell population.",
author = "Nima Sharifi and Hurt, {Elaine M.} and Farrar, {William L.}",
year = "2008",
month = "10",
doi = "10.1007/s00280-007-0659-5",
language = "English (US)",
volume = "62",
pages = "921--923",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Androgen receptor expression in prostate cancer stem cells

T2 - Is there a conundrum?

AU - Sharifi, Nima

AU - Hurt, Elaine M.

AU - Farrar, William L.

PY - 2008/10

Y1 - 2008/10

N2 - Androgen deprivation therapy (ADT) is standard frontline therapy for metastatic prostate cancer. However, prostate cancer progresses to a castrate-resistant state. The response of prostate cancer to androgen deprivation is mediated by the androgen receptor (AR). Castrate-resistant disease is marked by a gain-of-function in AR and AR reactivation. The stem cell hypothesis of cancer would therefore predict that AR should be expressed in the prostate cancer stem cell, since genetic selection for gain-of-function changes in AR, such as AR gene amplification, should occur at the level of the stem cell population. Initial reports characterizing prostate cancer stem cells suggest that AR is not expressed in this population, which is an apparent conundrum. Here, we examined the CD44+/24- LNCaP putative stem cell population by in-cell Western and show that AR is expressed at the protein level. Our findings suggest that at least a subset of prostate cancers express AR in the putative stem cell population.

AB - Androgen deprivation therapy (ADT) is standard frontline therapy for metastatic prostate cancer. However, prostate cancer progresses to a castrate-resistant state. The response of prostate cancer to androgen deprivation is mediated by the androgen receptor (AR). Castrate-resistant disease is marked by a gain-of-function in AR and AR reactivation. The stem cell hypothesis of cancer would therefore predict that AR should be expressed in the prostate cancer stem cell, since genetic selection for gain-of-function changes in AR, such as AR gene amplification, should occur at the level of the stem cell population. Initial reports characterizing prostate cancer stem cells suggest that AR is not expressed in this population, which is an apparent conundrum. Here, we examined the CD44+/24- LNCaP putative stem cell population by in-cell Western and show that AR is expressed at the protein level. Our findings suggest that at least a subset of prostate cancers express AR in the putative stem cell population.

UR - http://www.scopus.com/inward/record.url?scp=49749086189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49749086189&partnerID=8YFLogxK

U2 - 10.1007/s00280-007-0659-5

DO - 10.1007/s00280-007-0659-5

M3 - Article

C2 - 18075739

AN - SCOPUS:49749086189

VL - 62

SP - 921

EP - 923

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -